Influenza Vaccine Efficacy Induced by Orally Administered Recombinant Baculoviruses

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 May 28

PMID 32459823

Citations 5

Authors

Swarnendu Basak

Hae-Ji Kang

Su-Hwa Lee

Ki-Back Chu

Eun-Kyung Moon

Fu-Shi Quan

Affiliations

Soon will be listed here.

Abstract

Although vaccine delivery through the oral route remains the most convenient and safest way for mass immunization purposes, this method is limited by the requirement for large antigen doses and low vaccine efficacy. In this study, we generated recombinant baculoviruses (rBVs) expressing influenza hemagglutinin (A/PR/8/34) and orally delivered a low dose of rBVs to evaluate its vaccine efficacy in mice. Intranasal rBV vaccination was included in the whole experiment for comparison. We found that oral vaccination elicited high levels of virus-specific IgG and IgA antibody responses in both serum and mucosal samples (lung, tracheal, intestinal, fecal and vaginal). Surprisingly, complete protection from the lethal influenza challenge was observed, as indicated by reductions in the virus titer, inflammatory cytokine production, body weight change, and enhanced survival. These results suggest that oral delivery of the influenza rBV vaccine induces mucosal and systemic immunity, which protect mice from the lethal influenza virus challenge. Oral delivery of baculovirus vaccines can be developed as an effective vaccination route.

Citing Articles

Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses.

Jang H, Matsuoka M, Freire M Front Immunol. 2023; 14:1220610.

PMID: 37928529 PMC: 10622784. DOI: 10.3389/fimmu.2023.1220610.

Protective Immunity Induced by Immunization with Baculovirus, Virus-like Particle, and Vaccinia Virus Expressing the AMA1 of .

Kim M, Chu K, Kang H, Yoon K, Eom G, Mao J Biomedicines. 2022; 10(9).

PMID: 36140395 PMC: 9496152. DOI: 10.3390/biomedicines10092289.

Sublingual Vaccination with Live Influenza Virus Induces Better Protection Than Oral Immunization in Mice.

Mao J, Eom G, Yoon K, Kang H, Chu K, Quan F Life (Basel). 2022; 12(7).

PMID: 35888065 PMC: 9321673. DOI: 10.3390/life12070975.

Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus.

Kang H, Chu K, Yoon K, Eom G, Mao J, Quan F Biomedicines. 2022; 10(7).

PMID: 35884922 PMC: 9313027. DOI: 10.3390/biomedicines10071618.

Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.

Kang H, Chu K, Yoon K, Eom G, Mao J, Kim M Viruses. 2022; 14(2).

PMID: 35216022 PMC: 8875606. DOI: 10.3390/v14020429.

References

Hellfritzsch M, Scherliess R . Mucosal Vaccination via the Respiratory Tract. Pharmaceutics. 2019; 11(8). PMC: 6723941. DOI: 10.3390/pharmaceutics11080375. View

Mann J, Shakir E, Carter K, Mullen A, Alexander J, Ferro V . Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine. 2009; 27(27):3643-9. DOI: 10.1016/j.vaccine.2009.03.040. View

Nagaraja Shastri P, Kim M, Quan F, DSouza M, Kang S . Immunogenicity and protection of oral influenza vaccines formulated into microparticles. J Pharm Sci. 2012; 101(10):3623-35. PMC: 5558794. DOI: 10.1002/jps.23220. View

Criscuolo E, Caputo V, Diotti R, Sautto G, Kirchenbaum G, Clementi N . Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. J Immunol Res. 2019; 2019:8303648. PMC: 6425294. DOI: 10.1155/2019/8303648. View

Treanor J, Schiff G, Hayden F, Brady R, Hay C, Meyer A . Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007; 297(14):1577-82. DOI: 10.1001/jama.297.14.1577. View

Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J . Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol. 2010; 84(7):3201-9. PMC: 2838147. DOI: 10.1128/JVI.02175-09. View

Quan F, Compans R, Nguyen H, Kang S . Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2007; 82(3):1350-9. PMC: 2224423. DOI: 10.1128/JVI.01615-07. View

Kang H, Chu K, Lee D, Lee S, Park B, Kim M . Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLoS One. 2019; 14(6):e0216871. PMC: 6597044. DOI: 10.1371/journal.pone.0216871. View

Moon E, Kang H, Chu K, Lee S, Lee D, Soh Y . Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins. Immunol Invest. 2018; 48(4):355-366. DOI: 10.1080/08820139.2018.1544640. View

10.

Stagg A . Intestinal Dendritic Cells in Health and Gut Inflammation. Front Immunol. 2018; 9:2883. PMC: 6291504. DOI: 10.3389/fimmu.2018.02883. View

11.

Hunter Z, Smyth H, Durfee P, Chackerian B . Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine. 2009; 28(2):403-14. PMC: 2789199. DOI: 10.1016/j.vaccine.2009.10.035. View

12.

Kumar S, Syed Khader S, Kiener T, Szyporta M, Kwang J . Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus. PLoS One. 2013; 8(6):e63856. PMC: 3676417. DOI: 10.1371/journal.pone.0063856. View

13.

Levine M . Can needle-free administration of vaccines become the norm in global immunization?. Nat Med. 2003; 9(1):99-103. DOI: 10.1038/nm0103-99. View

14.

Shin C, Jeong S, Rejinold N, Kim Y . Microneedles for vaccine delivery: challenges and future perspectives. Ther Deliv. 2017; 8(6):447-460. DOI: 10.4155/tde-2017-0032. View

15.

Mann J, Ferro V, Mullen A, Tetley L, Mullen M, Carter K . Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine. 2004; 22(19):2425-9. DOI: 10.1016/j.vaccine.2003.11.067. View

16.

Giudice E, Campbell J . Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006; 58(1):68-89. DOI: 10.1016/j.addr.2005.12.003. View

17.

Tomar J, Patil H, Bracho G, Tonnis W, Frijlink H, Petrovsky N . Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. J Control Release. 2018; 288:199-211. PMC: 7111335. DOI: 10.1016/j.jconrel.2018.09.006. View

18.

Song J, van Rooijen N, Bozja J, Compans R, Kang S . Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2010; 108(2):757-61. PMC: 3021063. DOI: 10.1073/pnas.1012199108. View

19.

Quan F, Kim Y, Song J, Hwang H, Compans R, Prausnitz M . Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol. 2013; 20(9):1433-9. PMC: 3889580. DOI: 10.1128/CVI.00251-13. View

20.

Treanor J, Wilkinson B, Masseoud F, Battaglia R, OBrien D, Wolff M . Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001; 19(13-14):1732-7. DOI: 10.1016/s0264-410x(00)00395-9. View